FACULTY COMMENTS
DR ORLOWSKI: This paper examined the safety and efficacy of
bortezomib in patients who were at high risk and elderly patients
with relapsed disease. Indeed, older age by itself is a high-risk
feature in patients with multiple myeloma.
The findings show that for advanced ISS stage, patients age 65 or older and patients with more than one prior line of therapy, bortezomib continued to be superior to dexamethasone. The data here are similar to those for the overall APEX population.
DR LONIAL: In this subset analysis of the APEX trial, the
response rate for bortezomib in older patients with relapsed
disease was clearly as good as for younger patients. Among
patients who had received more than one prior line of therapy,
the response rate held up with 34 percent achieving a CR and
PR. I believe these are more confirmatory data.
| Table of Contents | Top of Page |
